Apellis Pharmaceuticals, Inc. (APLS) has 20 bekannte Insider- und institutionelle Anteilseigner verzeichnet. Der größte Anteilseigner ist Morningside Venture Investments Ltd mit 12,806,342 Aktien. Weitere bedeutende Anteilseigner sind Deschatelets Pascal und Francois Cedric.
In den letzten 12 Monaten haben Insider 86 Transaktionen in APLS Aktien getätigt — 32 Käufe (im Wert von $19.26M) und 39 Verkäufe (im Wert von $10.82M). Insider-Verkäufe haben die Käufe in diesem Zeitraum übertroffen.
APLS Insider-Beteiligungen
Größter Aktionär
Morningside Venture Investments Ltd
12,806,342 Aktien
Käufe (12 Monate)
32
$19.26M Wert
Verkäufe (12 Monate)
39
$10.82M Wert
12-Monats-Transaktionsaktivität
Top-Insider-Aktionäre
| # |
Name |
Funktion |
Gehaltene Aktien |
Zuletzt gemeldet |
Relative Größe |
| 1 |
Morningside Venture Investments Ltd |
10 Percent Owner |
12,806,342 |
2021-11-18 |
|
| 2 |
Deschatelets Pascal |
Chief Scientific Officer |
1,177,222 |
2026-01-30 |
|
| 3 |
Francois Cedric |
Chief Executive Officer |
372,815 |
2026-03-13 |
|
| 4 |
Sullivan Timothy Eugene |
Chief Financial Officer |
152,041 |
2026-01-30 |
|
| 5 |
Watson David O. |
General Counsel |
144,517 |
2026-01-30 |
|
| 6 |
Boucher Kelley |
Chief People Officer |
127,804 |
2026-01-30 |
|
| 7 |
Nicholson Nur |
Chief Technical Officer |
116,338 |
2026-01-30 |
|
| 8 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
114,591 |
2026-02-13 |
|
| 9 |
Meltzer Leslie |
Chief Research and Development |
107,024 |
2026-01-30 |
|
| 10 |
Grossi Federico |
Chief Medical Officer |
94,884 |
2023-01-09 |
|
| 11 |
Baumal Caroline |
Chief Medical Officer |
86,527 |
2026-01-23 |
|
| 12 |
Townsend Adam J. |
Chief Commercial Officer |
84,050 |
2025-01-30 |
|
| 13 |
Lewis Karen |
Chief People Officer |
70,251 |
2025-01-30 |
|
| 14 |
Chopas James George |
VP/chief Accounting Officer |
65,955 |
2026-01-30 |
|
| 15 |
Eisele Jeffrey |
Chief Development Officer |
55,312 |
2025-01-30 |
|
| 16 |
Scheibler Lukas |
Chief Research Officer |
39,391 |
2023-12-05 |
|
| 17 |
Brown Victoria L. |
Program Team Lead |
23,556 |
2023-01-24 |
|
| 18 |
Walbert Keli |
Director |
14,684 |
2026-01-05 |
|
| 19 |
Wheeler Craig A |
Director |
14,684 |
2026-01-05 |
|
| 20 |
Machiels Alec |
Director |
14,684 |
2026-01-05 |
|
Aktuelle Transaktionen (letzte 12 Monate)
| Datum |
Name |
Funktion |
Typ |
Aktien |
Kurs |
Wert |
| 2026-03-31 |
Biogen Inc. |
Other: See Footnotes |
Unbekannt |
- |
- |
- |
| 2026-03-11 |
Francois Cedric |
Chief Executive Officer |
Schenkung (erhalten) |
64,869 |
- |
- |
| 2026-03-02 |
Dolsten Mikael |
Director |
Unbekannt |
- |
- |
- |
| 2026-02-27 |
Dolsten Mikael |
Director |
RSU-Zuteilung |
14,312 |
- |
- |
| 2026-02-11 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
Informierter Verkauf |
368 |
$22.15 |
$8.15K |
| 2026-02-03 |
Francois Cedric |
Chief Executive Officer |
Optionsausübung (Verkauf) |
8,840 |
$3.76 |
$33.24K |
| 2026-01-28 |
Meltzer Leslie |
Chief Research and Development |
RSU-Zuteilung |
45,220 |
- |
- |
| 2026-01-28 |
Boucher Kelley |
Chief People Officer |
RSU-Zuteilung |
30,146 |
- |
- |
| 2026-01-28 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
RSU-Zuteilung |
36,606 |
- |
- |
| 2026-01-28 |
Chopas James George |
VP/chief Accounting Officer |
RSU-Zuteilung |
16,150 |
- |
- |
| 2026-01-28 |
Nicholson Nur |
Chief Technical Officer |
RSU-Zuteilung |
45,220 |
- |
- |
| 2026-01-28 |
Sullivan Timothy Eugene |
Chief Financial Officer |
RSU-Zuteilung |
58,140 |
- |
- |
| 2026-01-28 |
Francois Cedric |
Chief Executive Officer |
RSU-Zuteilung |
195,952 |
- |
- |
| 2026-01-28 |
Deschatelets Pascal |
Chief Scientific Officer |
RSU-Zuteilung |
25,840 |
- |
- |
| 2026-01-28 |
Watson David O. |
General Counsel |
RSU-Zuteilung |
55,986 |
- |
- |
| 2026-01-22 |
Baumal Caroline |
Chief Medical Officer |
Informierter Verkauf |
2,797 |
$21.77 |
$60.88K |
| 2026-01-22 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
Informierter Verkauf |
3,371 |
$21.77 |
$73.37K |
| 2026-01-22 |
Chopas James George |
VP/chief Accounting Officer |
Informierter Verkauf |
2,064 |
$21.77 |
$44.92K |
| 2026-01-22 |
Nicholson Nur |
Chief Technical Officer |
Informierter Verkauf |
7,725 |
$21.77 |
$168.14K |
| 2026-01-22 |
Sullivan Timothy Eugene |
Chief Financial Officer |
Informierter Verkauf |
10,287 |
$21.77 |
$223.9K |
| 2026-01-22 |
Francois Cedric |
Chief Executive Officer |
Informierter Verkauf |
27,192 |
$21.77 |
$591.84K |
| 2026-01-22 |
Deschatelets Pascal |
Chief Scientific Officer |
Informierter Verkauf |
5,928 |
$21.77 |
$129.03K |
| 2026-01-22 |
Watson David O. |
General Counsel |
Informierter Verkauf |
7,832 |
$21.77 |
$170.47K |
| 2026-01-20 |
Baumal Caroline |
Chief Medical Officer |
Informierter Verkauf |
1,882 |
$19.79 |
$37.25K |
| 2026-01-20 |
Delong Mark Jeffrey |
Chief Business & Strat Officer |
Informierter Verkauf |
1,334 |
$19.79 |
$26.4K |
